; (B) encourage domestic manufacturing, including consideration of economic impacts, if any; (C) improve supply chain information gaps; (D) improve planning considerations for medical product supply chain capacity during public health emergencies; and (E) promote the accessibility of such drugs and devices. (c) Input In conducting the study and developing the report under subsection (b), the National Academies shall— (1) consider input from the Department of Health and Human Services, the Department of Homeland Security, the Department of Defense, the Department of Commerce, the Department of State, the Department of Veterans Affairs, the Department of Justice, and any other Federal agencies as appropriate; and (2) consult with relevant stakeholders, which may include conducting public meetings and other forms of engagement, as appropriate, with health care providers, medical professional societies, State-based societies, public health experts, State and local public health departments, State medical boards, patient groups, medical product manufacturers, health care distributors, wholesalers and group purchasing organizations, pharmacists, and other entities with experience in health care and public health, as appropriate. (d) Definitions In this section, the terms device and drug have the meanings given such terms in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).